Pleioflow-HF is a minimally invasive blood flow assist device of a disruptive, innovative and patented technology featuring a self-expanding percutaneous catheter-mounted flow assist segment that is intended to provide temporary circulatory support for the left ventricle (LV) during high-risk percutaneous coronary interventions (HR-PCI) and in patients hospitalized with cardiogenic shock (CS) as well as post CPB low cardiac output cases.

In the course of HR-PCI and CS, the LV may require support in pumping oxygenated blood from the ventricle into the aorta, so that adequate cardiac output, arterial blood pressure and coronary and end-organ perfusion can be maintained. In large animal experiments, Pleioflow-HF flow assist device was shown to be able to direct and increase blood flow, both downstream and upstream, and augment the flow even in the upper circulation and the coronary arteries.

In addition, the Pleioflow devices have been shown -in post MI, large animal experiments- to reduce all, the LV end-diastolic pressure, the end-diastolic volume  and the end-systolic volume of the LV, thus decreasing both the myocardial wall stress and overall myocardial oxygen consumption at the same time.